FR22C1029I2 - Nouveaux promédicaments hgh polymériques - Google Patents

Nouveaux promédicaments hgh polymériques

Info

Publication number
FR22C1029I2
FR22C1029I2 FR22C1029C FR22C1029C FR22C1029I2 FR 22C1029 I2 FR22C1029 I2 FR 22C1029I2 FR 22C1029 C FR22C1029 C FR 22C1029C FR 22C1029 C FR22C1029 C FR 22C1029C FR 22C1029 I2 FR22C1029 I2 FR 22C1029I2
Authority
FR
France
Prior art keywords
new polymeric
polymeric hgh
prodrugs
hgh prodrugs
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1029C
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51951624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1029(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR22C1029I1 publication Critical patent/FR22C1029I1/fr
Application granted granted Critical
Publication of FR22C1029I2 publication Critical patent/FR22C1029I2/fr
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01GHORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G17/00Cultivation of hops, vines, fruit trees, or like trees
    • A01G17/005Cultivation methods
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01GHORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G2/00Vegetative propagation
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01GHORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G7/00Botany in general
    • A01G7/06Treatment of growing trees or plants, e.g. for preventing decay of wood, for tingeing flowers or wood, for prolonging the life of plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3348Polymers modified by chemical after-treatment with organic compounds containing sulfur containing nitrogen in addition to sulfur
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterized by the type of post-polymerisation functionalisation
    • C08G2650/06Epoxy-capping

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Forests & Forestry (AREA)
  • Ecology (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FR22C1029C 2014-11-18 2022-06-10 Nouveaux promédicaments hgh polymériques Active FR22C1029I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14193603 2014-11-18
EP15797642.4A EP3237014B1 (en) 2014-11-18 2015-11-17 Novel polymeric hgh prodrugs
PCT/EP2015/076813 WO2016079114A1 (en) 2014-11-18 2015-11-17 Novel polymeric hgh prodrugs

Publications (2)

Publication Number Publication Date
FR22C1029I1 FR22C1029I1 (fr) 2022-09-09
FR22C1029I2 true FR22C1029I2 (fr) 2023-04-14

Family

ID=51951624

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1029C Active FR22C1029I2 (fr) 2014-11-18 2022-06-10 Nouveaux promédicaments hgh polymériques

Country Status (26)

Country Link
US (2) US10799563B2 (lt)
EP (3) EP4218823A3 (lt)
JP (5) JP6783782B2 (lt)
KR (2) KR102608645B1 (lt)
AU (3) AU2015348633C1 (lt)
BR (1) BR112017009798A8 (lt)
CA (1) CA2968282A1 (lt)
CY (2) CY1123963T1 (lt)
DK (2) DK3653227T5 (lt)
ES (2) ES2947818T3 (lt)
FI (2) FI3237014T3 (lt)
FR (1) FR22C1029I2 (lt)
HR (1) HRP20210400T4 (lt)
HU (2) HUE053855T2 (lt)
IL (2) IL251906B2 (lt)
LT (2) LT3653227T (lt)
MX (2) MX2017006113A (lt)
NL (1) NL301172I2 (lt)
NO (1) NO2022014I1 (lt)
PL (1) PL3653227T6 (lt)
PT (1) PT3653227T (lt)
RS (1) RS61734B2 (lt)
RU (1) RU2718664C2 (lt)
SG (2) SG10202105511RA (lt)
SI (1) SI3653227T1 (lt)
WO (1) WO2016079114A1 (lt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE056849T2 (hu) 2014-11-21 2022-03-28 Ascendis Pharma Endocrinology Div A/S Hosszú hatástartalmú növekedési hormon adagolási formák
SG10202111952PA (en) 2016-09-29 2021-12-30 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
WO2019185706A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
EP3773680A1 (en) * 2018-03-28 2021-02-17 Ascendis Pharma Oncology Division A/S Il-2 conjugates
AU2020204785A1 (en) 2019-01-04 2021-06-03 Ascendis Pharma Oncology Division A/S Sustained local drug levels for innate immune agonists
AU2020204970A1 (en) 2019-01-04 2021-06-24 Ascendis Pharma Oncology Division A/S Conjugates of pattern recognition receptor agonists
CA3125488A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
US20220054478A1 (en) 2019-01-04 2022-02-24 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
US20220088147A1 (en) * 2019-03-04 2022-03-24 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
KR20230019889A (ko) 2020-06-03 2023-02-09 아센디스 파마 온콜로지 디비전 에이/에스 Il-2 서열 및 이의 용도
KR20230164709A (ko) 2021-04-01 2023-12-04 아센디스 파마 에이에스 염증 유발 질환을 치료하기 위한 지속형 성장 호르몬의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011197A (en) * 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
EP1625855A1 (en) 2004-08-13 2006-02-15 Complex Biosystems GmbH Polymeric prodrug with a self-immolative linker
WO2005099768A2 (en) * 2004-03-23 2005-10-27 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
EP1579873A1 (en) * 2004-03-23 2005-09-28 Complex Biosystems GmbH Polymeric prodrugs
US20060233740A1 (en) * 2005-03-23 2006-10-19 Bossard Mary J Conjugates of an hGH moiety and a polymer
EP2113256A1 (en) * 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
CN102989001B (zh) * 2008-04-29 2014-12-03 阿森迪斯药物生长障碍股份有限公司 Peg化的重组人生长激素化合物
RU2012129674A (ru) * 2009-12-15 2014-01-27 Аспендис Фарма Ас Композиция гормона роста
US20220088147A1 (en) * 2019-03-04 2022-03-24 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin

Also Published As

Publication number Publication date
FI3237014T3 (fi) 2023-06-09
MX2022009155A (es) 2022-08-16
AU2015348633C1 (en) 2021-02-11
US10799563B2 (en) 2020-10-13
IL251906B1 (en) 2023-12-01
JP6783782B2 (ja) 2020-11-11
KR102608645B1 (ko) 2023-12-01
NZ731779A (en) 2021-11-26
FR22C1029I1 (fr) 2022-09-09
EP4218823A3 (en) 2023-11-15
ES2947818T3 (es) 2023-08-21
DK3653227T3 (da) 2021-02-15
EP4218823A2 (en) 2023-08-02
JP7210683B2 (ja) 2023-01-23
CY1123963T1 (el) 2022-05-27
AU2015348633A1 (en) 2017-05-18
IL251906B2 (en) 2024-04-01
ES2864415T9 (es) 2023-05-23
IL307773A (en) 2023-12-01
MX2017006113A (es) 2017-10-16
PT3653227T (pt) 2021-02-26
ES2864415T3 (es) 2021-10-13
DK3653227T5 (da) 2023-08-21
US20170354716A1 (en) 2017-12-14
DK3237014T3 (da) 2023-05-30
EP3653227A1 (en) 2020-05-20
SG11201703870UA (en) 2017-06-29
JP2023052300A (ja) 2023-04-11
JP2021020932A (ja) 2021-02-18
AU2020270494A1 (en) 2020-12-17
KR20170084267A (ko) 2017-07-19
HRP20210400T1 (hr) 2021-04-16
PL3653227T3 (pl) 2021-07-05
DK3237014T5 (da) 2024-10-14
JP6982156B2 (ja) 2021-12-17
US20200390864A1 (en) 2020-12-17
BR112017009798A8 (pt) 2020-11-03
EP3653227B1 (en) 2021-01-20
RU2718664C2 (ru) 2020-04-13
JP2017535609A (ja) 2017-11-30
DK3653227T6 (da) 2022-04-11
RU2017121203A3 (lt) 2019-05-30
LTPA2022506I1 (lt) 2022-06-10
SI3653227T1 (sl) 2021-04-30
LT3653227T (lt) 2021-03-25
EP3237014A1 (en) 2017-11-01
BR112017009798A2 (pt) 2017-12-19
NL301172I1 (nl) 2022-04-29
PL3653227T6 (pl) 2022-04-19
AU2015348633B2 (en) 2020-10-22
KR20230152187A (ko) 2023-11-02
AU2020270494B2 (en) 2024-02-01
CY2022013I1 (el) 2023-01-05
JP2024054177A (ja) 2024-04-16
HRP20210400T4 (hr) 2022-04-29
EP3653227B3 (en) 2022-03-09
AU2024201227A1 (en) 2024-03-28
NO2022014I1 (no) 2022-05-12
RU2017121203A (ru) 2018-12-19
EP3653227B9 (en) 2023-03-08
HUS2200019I1 (hu) 2022-06-28
HUE053855T2 (hu) 2021-07-28
FIC20220017I1 (fi) 2022-06-03
CA2968282A1 (en) 2016-05-26
WO2016079114A1 (en) 2016-05-26
NL301172I2 (nl) 2022-06-16
RS61734B2 (sr) 2022-04-29
RS61734B1 (sr) 2021-05-31
IL251906A0 (en) 2017-06-29
JP7431355B2 (ja) 2024-02-14
EP3237014B1 (en) 2023-03-29
ES2864415T7 (es) 2022-05-12
CY2022013I2 (el) 2023-01-05
SG10202105511RA (en) 2021-07-29
JP2022033787A (ja) 2022-03-02

Similar Documents

Publication Publication Date Title
FR22C1029I2 (fr) Nouveaux promédicaments hgh polymériques
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3119396T3 (da) Muscarinreceptoragonister
MA55696A (fr) Combinaisons
DK3006072T3 (da) Karadgang
DK3102254T3 (da) Injektionsindretning
DE112015001664A5 (de) Betätigungsaktuator
DK3183340T3 (da) Termolabile exonukleaser
DK3294287T3 (da) Oxabicycloheptan-prodrugs
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DK3110439T3 (da) Pcsk9-vacciner
DE112015005041A5 (de) Gargerätevorrichtung
DE102014000623A8 (de) Halbhohlnietelement
DK3288391T3 (da) Fodertilsætningsstof
DK3009858T3 (da) Skyradar
DE112015001633A5 (de) Betätigungsaktuator
DK3091875T3 (da) Vipbar taburet
DE202014005655U8 (de) llluminationsvorrichtung
TH177000B (th) การย่อยสลายพอลิเมอร์
ES1147358Y (es) Servilletero mejorado
ITUB20153420A1 (it) Cerotto
DE112015005055A5 (de) Gargerätevorrichtung
DE112015004618A5 (de) Garnitur
TH1601003403A (th) วิธิการผสมพันธุ์ระดับโมเลกุลที่ได้รับการปรับปรุงให้ดีขึ้น